You are here

  • Home
  • Archive
  • Volume 102, Issue Suppl 6
  • 109 Marked Differences in the Pharmacodynamics of Modern P2Y12 Inhibitors in Patients Undergoing Treatment for ST Segment Elevation MI (STEMI) and Non ST Segment Elevation MI (NSTEMI)

Article Text

Article menu

Download PDFPDF

Heart View
Acute Coronary Syndromes
109 Marked Differences in the Pharmacodynamics of Modern P2Y12 Inhibitors in Patients Undergoing Treatment for ST Segment Elevation MI (STEMI) and Non ST Segment Elevation MI (NSTEMI)
Free
  1. Vincent Amoah1,
  2. Nazish Khan1,
  3. Andrew Smallwood2,
  4. Ben Wrigley2,
  5. Joe Martins3,
  6. Saib Khogali2,
  7. Shahzad Munir2,
  8. Nevill Alan4,
  9. James Cotton1
  1. 1The Royal Wolverhampton Hospitals NHS Trust
  2. 2The Royal Wolvehampton Hospitals NHS Trust
  3. 3The Dudley Group of Hospitals
  4. 4University of Wolverhampton

Abstract

Introduction Current pharmacodynamic (PD) data suggest reduced antiplatelet effect in ST-Elevation myocardial infarction (STEMI) of prasugrel and ticagrelor. We sought to investigate the early PD effect of prasugrel and ticagrelor administered in two patient groups: those admitted with STEMI and a cohort admitted with NSTEMI/unstable angina (UA).

Methods P2Y12 inhibitor naïve patients presenting with STEMI or NSTEMI/UA were assessed for inclusion. All patients provided informed consent. All received aspirin (300mg) and loading dose of either prasugrel (60mg) or ticagrelor (180mg) in a non-randomised fashion. Platelet reactivity was measured using VerifyNow assay at 20 min, 1 and 4 h post loading. Results are expressed a P2Y12 reaction units (PRU). PRU≥208 indicates a sub optimal antiplatelet response. PRU over time was tested between groups using 2 way ANOVA, P < 0.05 was considered significant.

Results A total of 58 patients were enrolled (30 STEMI, and 28 NSTEMI/UA Table 1).

View this table:
Abstract 109 Table 1

Baseline characteristics

Results are shown in Fig 1. In the STEMI patients there was little effect of either agent at 20 min post loading (prasugrel PRU 247 + 48.8, ticagrelor PRU 256 + 50.8) with a limited effect at 1 h and persisting attenuated results at 4 h. In the NSTEMI group however there was a marked and rapid antiplatelet effect of both agents at all time points. Over time there was a significant difference between the effect of both prasugrel ( P < 0.001) and ticagrelor ( P < 0.001) in STEMI patients vs NSTEMI patients. There was no significant difference in the effect of ticagrelor vs prasugrel over time in either STEMI or NSTEMI/UA.

Abstract 109 Figure 1
Abstract 109 Figure 1

The degree of inhibition of platelet reactivity (expressed as PRU) over time following the administration of prasugrel (A) and ticagrelor (B) in STEMI and NSTEMI patients. PRU = P2Y12 reactivity units

Conclusion Prasugrel and ticagrelor in the context of STEMI do not provide adequate P2Y12 inhibition at reperfusion and the first hour post loading when compared to patients with NSTEMI/UA.

  • P2Y12 inhbitors
  • Platelet Function
  • ACS

http://dx.doi.org/10.1136/heartjnl-2016-309890.109

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.